Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Persistent Thrombocytopenia and Neutropenia Are Associated with Increased Mortality in Patients Treated with Anti-BCMA CAR T Cells for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7095.

https://doi.org/10.1182/blood-2024-202101

Published: 2024

Journal Articles

The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution

Blood (2024) 144 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2024-210746

Published: 2024

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

Enrique M Ocio, Aurore Perrot, Pierre Bories, Jesús F. San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Song-Yau Wang, Sara Bringhen, Maria-Victoria Mateos, Paula Rodríguez-Otero, Stefania Oliva, Axel Nogai, Bruno Paiva, Yi Li, Eric Le Bras, Sandrine Macé, Ercem Kodas, Helgi Van de Velde, Philippe Moreau

Blood (2024) 144 (Supplement 1): 1976.

https://doi.org/10.1182/blood-2024-200135

Published: 2024

Journal Articles

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 453.

https://doi.org/10.1182/blood-2023-187371

Published: 2023

Journal Articles

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Vladan Vucinic, Janine Kirchberg, Mandy Brueckner, Patrick Born, Luise Fischer, Enrica Bach, Nora Grieb, Simone Heyn, Christina Kloetzer, Klaus H Metzeler, Sandra Hoffmann, Carmen Herling, Marco Herling, Georg-Nikolaus Franke, Sebastian Schwind, Song-Yau Wang, Madlen Jentzsch, Uwe Platzbecker, Maximilian Merz

Blood (2023) 142 (Supplement 1): 3521.

https://doi.org/10.1182/blood-2023-182222

Published: 2023

Journal Articles

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2023-188367

Published: 2023

Journal Articles

30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study

Enrique M Ocio, Aurore Perrot, Philippe Moreau, Maria-Victoria Mateos, Sara Bringhen, Joaquin Martinez-Lopez, Lionel Karlin, Igor Wolfgang Blau, Song-Yau Wang, Maurizio Martelli, Corina Oprea, Yvonne Dong, Ercem Kodas, Jesus San Miguel

Blood (2023) 142 (Supplement 1): 6717.

https://doi.org/10.1182/blood-2023-175020

Published: 2023

Journal Articles

Increased Bone Turnover and Decreased BCMA Levels in Patients with Response to Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Jule Ussmann, Luise Fischer, Patrick Born, Nora Grieb, Sandra Hoffmann, Ronny Baber, Song-Yau Wang, Christina Kloetzer, Simone Heyn, Marco Herling, Carmen Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Lorenz Hofbauer, Uwe Platzbecker, Vladan Vucinic, Heike Weidner, Maximilian Merz

Blood (2023) 142 (Supplement 1): 6643.

https://doi.org/10.1182/blood-2023-185643

Published: 2023

Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Blood (2022) 140 (Supplement 1): 10185–10188.

https://doi.org/10.1182/blood-2022-162336

Published: 2022

Journal Articles

Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed Therapies

Maximilian Merz, Vladan Vucinic, Song Yau Wang, Christina Kloetzer, Birthe Schetschorke, Jan Sonntag, Jule Ussmann, Saskia Hell, Simone Heyn, Sandra Hoffmann, Enrica Bach, Klaus H. Metzeler, Sebastian Schwind, Marco Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 12492–12493.

https://doi.org/10.1182/blood-2022-164591

Published: 2022

Journal Articles

Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Blood (2022) 140 (Supplement 1): 4207–4208.

https://doi.org/10.1182/blood-2022-166241

Published: 2022

Journal Articles

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Blood (2021) 138 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2021-150311

Published: 2021

Journal Articles

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Nadia Jaekel, MD, Karolin Hubert, Mathias Hänel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Susann Schulze, MD, Song-Yau Wang, MD, Christoph Kahl, MD, Maxi Wass, MD, Herbert G. Sayer, MD PhD, Oana Brosteanu, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali

Blood (2018) 132 (Supplement 1): 83.

https://doi.org/10.1182/blood-2018-99-115790

Published: 2018

Journal Articles

Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

Nadia Jaekel, MD, Karolin Hubert, Rainer Krahl, PhD, M Haenel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Christian Jakob, MD, Susann Schulze, Song-Yau Wang, Michael Cross, PhD, Christoph Kahl, MD, Maxi Wass, MD, Herbert G. Sayer, MD PhD, Oana Brosteanu, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali

Blood (2017) 130 (Supplement 1): 1334.

https://doi.org/10.1182/blood.V130.Suppl_1.1334.1334

Published: 2017

Journal Articles

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

Haifa Kathrin Al-Ali, MD, Nadja Jaekel, MD, Karolin Hubert, Rainer Krahl, PhD, Mathias Haenel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Christian Jakob, MD, Susann Schultze, MD, Song-Yau Wang, MD, Oana Brosteanu, PhD, Dietger Niederwieser, MD

Blood (2015) 126 (23): 1346.

https://doi.org/10.1182/blood.V126.23.1346.1346

Published: 2015

Journal Articles

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

Nadja Jaekel, MD, Song-Yau Wang, MD, Rainer Krahl, PhD, Karolin Hubert, Susann Schulze, MD, Rayk Stengel, PhD, Melanie Schneider, Martin Roskos, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali, MD

Blood (2015) 126 (23): 2014.

https://doi.org/10.1182/blood.V126.23.2014.2014

Published: 2015

Journal Articles

Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma

Madlen Jentzsch, MD, Elena Ruschpler, Sabine Leiblein, PhD, Yvonne Remane, Jan-Phillip Stümpel, MD, Georg-Nikolaus Franke, MD, Simone Heyn, MD, Nadja Jaekel, MD, Susann Schulze, MD, Song-Yau Wang, MD, Wolfram Poenisch, MD, Claudia Nehring, MD, Sebastian Schwind, MD, Dietger Niederwieser, MD, Vladan Vucinic, MD

Blood (2015) 126 (23): 5439.

https://doi.org/10.1182/blood.V126.23.5439.5439

Published: 2015

Journal Articles

The Prognostic Impact of the Mutational Profile in Patients with Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib

Haifa Kathrin Al-Ali, MD, Song-Yau Wang, Nadja Jaekel, MD, Anne Koehler, MD, Rainer Krahl, PhD, Karolin Hubert, Mrs, Thoralf Lange, MD, Martin Roskos, PhD, Rayak Stengel, PhD, Ines Kovacs, Mrs, Schwabe Scarlett, Mrs, Karoline Schubert, Kathrin Wildenberger, Melanie Schneider, Mrs, Elisabeth Koehler, Mrs, Dietger Niederwieser, MD

Blood (2014) 124 (21): 1860.

https://doi.org/10.1182/blood.V124.21.1860.1860

Published: 2014

Journal Articles

High Levels of Nm23-H2 Protein Are a Specific and Invariable Feature of CML-CP Cells Due to Post Transcriptional Control Via a Bcr-Abl Dependent Pathway

Sabine Tschiedel, Michael Cross, Enrica Müller, Annette Jilo, Song-Yau Wang, Vladan ucinic, Thoralf Lange, MD, Haifa Kathrin Al-Ali, MD, Dietger W Niederwieser, MD

Blood (2010) 116 (21): 4461.

https://doi.org/10.1182/blood.V116.21.4461.4461

Published: 2010

Journal Articles

BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses.

Oliver Pelz-Ackermann, Michael W.N. Deininger, PhD, Michael Cross, PhD, Kathrin Wildenberger, Rainer Krahl, PhD, Song-Yau Wang, MD, Haifa K. Al-Ali, MD, Dietger W. Niederwieser, MD, Thoralf Lange, MD

Blood (2007) 110 (11): 2918.

https://doi.org/10.1182/blood.V110.11.2918.2918

Published: 2007

NARROW

Persistent Thrombocytopenia and Neutropenia Are Associated with Increased Mortality in Patients Treated with Anti-BCMA CAR T Cells for Relapsed/Refractory Multiple Myeloma

The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study

Increased Bone Turnover and Decreased BCMA Levels in Patients with Response to Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed Therapies

Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO)

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma

The Prognostic Impact of the Mutational Profile in Patients with Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib

High Levels of Nm23-H2 Protein Are a Specific and Invariable Feature of CML-CP Cells Due to Post Transcriptional Control Via a Bcr-Abl Dependent Pathway

BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only